CAR-T therapy and Antibody-drug conjugates (ADCs) have been explored separately as therapeutic options for beating cancer. But instead of considering each separately, what if the answer is to merge them? This paper by Xin et al does something unique: turning CAR-T cells into their own drug delivery systems.

The Problem

Background Science

What They Did

What's New?

My Interpretation

What I'd Do Next

Something I Learned

My Favorite Figure

---

References